Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 18/20 | 0.61 |
| ▸ | OXTR | P30559 | 8/20 | 0.53 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.50 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232002 | 0.90 | AVPR2 (0.76) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL5236838 | 0.81 | AVPR2 (0.66) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL5233767 | 0.81 | AVPR2 (0.63) | AVPR2 | |
| SCHEMBL5229038 | 0.78 | AVPR2 (0.60) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL5523742 | 0.78 | AVPR2 (0.68) | AVPR2AVPR1A | |
| SCHEMBL5228515 | 0.78 | AVPR2 (0.89) | AVPR2 | |
| SCHEMBL6202224 | 0.78 | AVPR1A (0.54) | AVPR2OXTRAVPR1AAVPR1B | |
| Hydrochloric Acid SCHEMBL5236127 | 0.78 | AVPR2 (0.56) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL5233090 | 0.77 | AVPR2 (0.60) | AVPR2 | |
| Hydrochloric Acid SCHEMBL5232996 | 0.77 | AVPR1A (0.53) | AVPR2OXTRAVPR1AAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294698-B1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING BV (NL) | 2007-08-01 | — | — | EP | claimed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | claimed |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | VANTIA LIMITED (GB) | 2004-02-26 | — | — | US | claimed |
| EP-1294698-B1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING BV (NL) | 2007-08-01 | — | — | EP | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | VANTIA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885OXTR 21/4885AVPR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.